Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma 11Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Leukemia, B-Cell 8Recurrence 7Lymphoma, Large B-Cell, Diffuse 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Thrombocytopenia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphoma, B-Cell 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1Bronchiolitis Obliterans Syndrome 1Agammaglobulinemia 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × ofatumumab × Clear all
NCT01376713 2015-10-06

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

Medical University of Vienna

Phase 2 Completed
10 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡